NCT06791915

Brief Summary

Radiofrequency ablation (RFA) for atrial fibrillation (AF) is performed under general anesthesia. The success of the procedure depends on the safe contact of the catheter electrode with the myocardium. Movement of the catheter tip due to respiratory changes can result in inadequate lesion formation and AF recurrence. The success of AF ablation depends on the adequacy of energy delivered to the myocardium and the durability of pulmonary vein isolation (PVI). Poor energy delivery and tissue heating during ablation are a major cause of procedural failure in RFA. To improve the success of the PVI procedure, efforts are underway to optimize catheter stability and contact force. However, catheter force and stability are influenced by respiration-induced thoracic motion, highlighting the importance of controlled breathing for further optimization. Fluoroscopy and ablation times during electroanatomic mapping-guided AF ablations improved with controlled mechanical ventilation. General anesthesia improved catheter contact. Low tidal volume, high respiratory rate (FCV), pressure controlled mechanical ventilation (PCV), volume controlled mechanical ventilation (VCV), pressure controlled volume assured mechanical ventilation (PRVC) can be used in investigators' hospital. The literature offers no definitive proof that one ablation procedure is superior to another.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2025

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

January 7, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 24, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

January 24, 2025

Status Verified

January 1, 2025

Enrollment Period

6 months

First QC Date

January 7, 2025

Last Update Submit

January 23, 2025

Conditions

Keywords

Atrial FibrillationAblationgeneral anesthesia

Outcome Measures

Primary Outcomes (3)

  • Radiofrequency ablation procedure duration.

    The effect of mechanical ventilation mode during radiofrequency ablation procedure on procedure duration.

    At the end of the ablation procedure (Ablation time varies between 1 and 3 hours)

  • Change From Baseline Electrocardiography After Radiofrequency Ablation.

    Change in baseline ECG during radiofrequency ablation procedure showing the effect of mechanical ventilation mode on procedural success.

    At the end of the ablation procedure (Ablation time varies between 1 and 3 hours)

  • After radiofrequency ablation procedure atrial fibrillation recurrence rate.

    The effect of mechanical ventilation mode during radiofrequency ablation procedure on atrial fibrillation recurrence rate.

    In one month after procedure.

Study Arms (2)

Flow Controlled Mechanical Ventilation (FCV)

Controlled ventilation parameters and hemodynamic and respiratory values (systolic pressure, diastolic pressure, peak heart rate, peripheral oxygen saturation, fraction of inspired oxygen (FiO2)), and Bispectral Index monitoring (BIS) values in the patient's preferred FCV mode will be recorded. Ablation lesion parameters including mean ablation time per lesion, mean contact force, mean impedance drop, mean ablation index, and procedural characteristics including total procedure time, total ablation time, and total RF time will also be recorded. Clinical outcomes, including freedom from all atrial arrhythmias and short and long-term procedural complications, will also be recorded at routine patient follow-up.

Procedure: Radiofrequency Ablation with FCV.

Volume Controlled Mechanical Ventilation (VCV)

Controlled ventilation parameters and hemodynamic and respiratory values (systolic pressure, diastolic pressure, peak heart rate, peripheral oxygen saturation, fraction of inspired oxygen (FiO2)), and Bispectral Index monitoring (BIS) values in the patient's preferred VCV mode will be recorded. Ablation lesion parameters including mean ablation time per lesion, mean contact force, mean impedance drop, mean ablation index, and procedural characteristics including total procedure time, total ablation time, and total RF time will also be recorded. Clinical outcomes, including freedom from all atrial arrhythmias and short and long-term procedural complications, will also be recorded at routine patient follow-up.

Procedure: Radiofrequency Ablation with VCV.

Interventions

Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Flow Controlled Mechanical Ventilation (FCV).

Flow Controlled Mechanical Ventilation (FCV)

Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Volume Controlled Mechanical Ventilation (VCV).

Volume Controlled Mechanical Ventilation (VCV)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All ASA I-II-III patients over 18 years of age with a diagnosis of atrial fibrillation who were planned to receive radiofrequency ablation treatment under general anesthesia.

You may qualify if:

  • Diagnosed with atrial fibrillation
  • planned to receive radiofrequency ablation treatment under general anesthesia
  • all patients over 18 years of age

You may not qualify if:

  • \- Patients undergoing ablation under sedation and/or local anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kocaeli City Hospital

Kocaeli, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Radiofrequency AblationFamciclovir

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Radiofrequency TherapyTherapeuticsAblation TechniquesSurgical Procedures, OperativeAdeninePurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 7, 2025

First Posted

January 24, 2025

Study Start

January 1, 2025

Primary Completion

July 1, 2025

Study Completion

August 1, 2025

Last Updated

January 24, 2025

Record last verified: 2025-01

Locations